Altimmune, Inc. Common Stock (ALT) Stock Price

ALTStock

$3.20−12.15%52W

Market Cap$622.46M

P/E—

PEG Ratio32.62

Div yield—

Beta0.01

ALT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.52%

Price vs S&P 500 (4W)0.96%

PEG Ratio32.62

VGM Score41.76

Book Value / Share (Quarterly)$2.18

P/TBV (Annual)3.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-83.45%

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-25.81%

Net Profit Margin (TTM)-214860.98%

EPS (TTM)$-0.92

10-Day Avg Trading Volume4.78M

EPS Excl Extra (TTM)$-0.92

Revenue Growth (5Y)-65.33%

EPS (Annual)$-1.00

ROI (Annual)-33.99%

Gross Margin (Annual)100.47%

Net Profit Margin (5Y Avg)-142743.71%

Cash / Share (Quarterly)$2.55

Revenue Growth QoQ (YoY)420.00%

ROA (Last FY)-31.47%

Revenue Growth TTM (YoY)80.00%

EBITD / Share (TTM)$-0.97

ROE (5Y Avg)-51.24%

Operating Margin (TTM)-230460.98%

Cash Flow / Share (Annual)$-0.61

P/B Ratio1.97x

P/B Ratio (Quarterly)1.41x

Net Income / Employee (Annual)$-1,545,500

EV / Revenue (TTM)12097.98x

Net Interest Coverage (TTM)-15.42x

ROA (TTM)-35.57%

EPS Incl Extra (Annual)$-1.00

Current Ratio (Annual)18.55x

Quick Ratio (Quarterly)29.43x

3-Month Avg Trading Volume4.51M

52-Week Price Return-12.15%

Revenue / Employee (TTM)$600

Tangible BV / Share (Quarterly)$2.75

P/S Ratio (Annual)13636.91x

Asset Turnover (Annual)0.00x

52-Week High$6.44

Operating Margin (5Y Avg)-154341.23%

EPS Excl Extra (Annual)$-1.00

CapEx CAGR (5Y)-49.65%

Tangible BV CAGR (5Y)41.27%

26-Week Price Return-30.27%

Quick Ratio (Annual)18.35x

13-Week Price Return6.14%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)29.56x

Enterprise Value$496.02M

Revenue / Share Growth (5Y)-72.53%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-19.74%

Revenue / Employee (Annual)$700

Pretax Margin (Annual)-216521.95%

Cash / Share (Annual)$2.47

3-Month Return Std Dev46.24%

Net Income / Employee (TTM)$-1,597,900

ROE (Last FY)-39.17%

Net Interest Coverage (Annual)-881.33x

EPS Basic Excl Extra (Annual)$-1.00

P/FCF (TTM)3106.18x

Receivables Turnover (TTM)0.03x

Total Debt / Equity (Quarterly)0.12x

EPS Incl Extra (TTM)$-0.92

Receivables Turnover (Annual)0.05x

ROI (TTM)-38.21%

P/S Ratio (TTM)13636.91x

Pretax Margin (5Y Avg)-143089.14%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.75

Price vs S&P 500 (52W)-30.46%

Year-to-Date Return-13.85%

5-Day Price Return4.71%

EPS Normalized (Annual)$-1.00

ROA (5Y Avg)-45.40%

Net Profit Margin (Annual)-214860.98%

Month-to-Date Return9.51%

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-230460.98%

LT Debt / Equity (Annual)0.15x

ROI (5Y Avg)-50.20%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-0.92

P/TBV (Quarterly)3.11x

P/B Ratio (Annual)1.67x

Pretax Margin (TTM)-216521.95%

Book Value / Share (Annual)$2.03

Price vs S&P 500 (13W)3.35%

Beta0.01x

P/FCF (Annual)1016.57x

Revenue / Share (TTM)$0.00

ROE (TTM)-42.57%

52-Week Low$2.56

vGradeF

gGradeC

mGradeC

vgmGradeC

ALT Earnings Surprise History

Q2 25-0.27est. -0.32

Q3 25-0.21est. -0.27

Q4 25-0.27est. -0.24

Q1 26-0.18est. -0.25

Q2 26-0.12est. -0.13

ALT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.06

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALTAltimmune, Inc. Common Stock	F	C	C	$3.20
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Altimmune, Inc. Common Stock

Altimmune is a clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a dual GLP-1/glucagon receptor agonist in late-stage development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The balanced 1:1 dual-receptor mechanism differentiates pemvidutide within the metabolic disease space, with the company exploring additional indications to expand its addressable market.